170 related articles for article (PubMed ID: 22577058)
1. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.
Hildebrandt MA; Lippman SM; Etzel CJ; Kim E; Lee JJ; Khuri FR; Spitz MR; Lotan R; Hong WK; Wu X
Clin Cancer Res; 2012 Jul; 18(13):3705-13. PubMed ID: 22577058
[TBL] [Abstract][Full Text] [Related]
2. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients.
Lee JJ; Wu X; Hildebrandt MA; Yang H; Khuri FR; Kim E; Gu J; Ye Y; Lotan R; Spitz MR; Hong WK
Cancer Prev Res (Phila); 2011 Feb; 4(2):185-93. PubMed ID: 21292633
[TBL] [Abstract][Full Text] [Related]
3. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants.
Wu X; Spitz MR; Lee JJ; Lippman SM; Ye Y; Yang H; Khuri FR; Kim E; Gu J; Lotan R; Hong WK
Cancer Prev Res (Phila); 2009 Jul; 2(7):617-24. PubMed ID: 19584075
[TBL] [Abstract][Full Text] [Related]
4. Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma.
Wang J; Lippman SM; Lee JJ; Yang H; Khuri FR; Kim E; Lin J; Chang DW; Lotan R; Hong WK; Wu X
Carcinogenesis; 2010 Oct; 31(10):1755-61. PubMed ID: 20627871
[TBL] [Abstract][Full Text] [Related]
5. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial.
Khuri FR; Kim ES; Lee JJ; Winn RJ; Benner SE; Lippman SM; Fu KK; Cooper JS; Vokes EE; Chamberlain RM; Williams B; Pajak TF; Goepfert H; Hong WK
Cancer Epidemiol Biomarkers Prev; 2001 Aug; 10(8):823-9. PubMed ID: 11489748
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590).
Bhatia AK; Lee JW; Pinto HA; Jacobs CD; Limburg PJ; Rubin P; Arusell RM; Dunphy EP; Khandekar JD; Reiner SA; Baez-Diaz L; Celano P; Li S; Li Y; Burtness BA; Adams GL; Pandya KJ
Cancer; 2017 Dec; 123(23):4653-4662. PubMed ID: 28786105
[TBL] [Abstract][Full Text] [Related]
7. PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.
Pfisterer K; Fusi A; Klinghammer K; Knödler M; Nonnenmacher A; Keilholz U
Head Neck; 2015 Apr; 37(4):471-8. PubMed ID: 24421178
[TBL] [Abstract][Full Text] [Related]
8. A strong case for personalized, targeted cancer prevention.
Dawson MI
Cancer Prev Res (Phila); 2011 Feb; 4(2):173-6. PubMed ID: 21292632
[TBL] [Abstract][Full Text] [Related]
9. 13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group.
Toma S; Bonelli L; Sartoris A; Mira E; Antonelli A; Beatrice F; Giordano C; Benazzo M; Caroggio A; Cavalot AL; Gandolfo S; Garozzo A; Margarino G; Schenone G; Spadini N; Sirotovà Z; Zibordi F; Balzarini F; Serafini I; Miani P; Cortesina G
Oncol Rep; 2004 Jun; 11(6):1297-305. PubMed ID: 15138569
[TBL] [Abstract][Full Text] [Related]
10. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.
Shin DM; Khuri FR; Murphy B; Garden AS; Clayman G; Francisco M; Liu D; Glisson BS; Ginsberg L; Papadimitrakopoulou V; Myers J; Morrison W; Gillenwater A; Ang KK; Lippman SM; Goepfert H; Hong WK
J Clin Oncol; 2001 Jun; 19(12):3010-7. PubMed ID: 11408495
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer.
Zhang X; Yang H; Lee JJ; Kim E; Lippman SM; Khuri FR; Spitz MR; Lotan R; Hong WK; Wu X
Carcinogenesis; 2010 Dec; 31(12):2118-23. PubMed ID: 20819778
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of head and neck cancer with retinoids: a negative result.
Perry CF; Stevens M; Rabie I; Yarker ME; Cochrane J; Perry E; Traficante R; Coman W
Arch Otolaryngol Head Neck Surg; 2005 Mar; 131(3):198-203. PubMed ID: 15781758
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer.
Minard CG; Spitz MR; Wu X; Hong WK; Etzel CJ
Cancer; 2006 Jun; 106(12):2636-44. PubMed ID: 16703596
[TBL] [Abstract][Full Text] [Related]
14. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
Hildebrandt MA; Yang H; Hung MC; Izzo JG; Huang M; Lin J; Ajani JA; Wu X
J Clin Oncol; 2009 Feb; 27(6):857-71. PubMed ID: 19164214
[TBL] [Abstract][Full Text] [Related]
15. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
Khuri FR; Lee JJ; Lippman SM; Kim ES; Cooper JS; Benner SE; Winn R; Pajak TF; Williams B; Shenouda G; Hodson I; Fu K; Shin DM; Vokes EE; Feng L; Goepfert H; Hong WK
J Natl Cancer Inst; 2006 Apr; 98(7):441-50. PubMed ID: 16595780
[TBL] [Abstract][Full Text] [Related]
17. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma.
Pedrero JM; Carracedo DG; Pinto CM; Zapatero AH; Rodrigo JP; Nieto CS; Gonzalez MV
Int J Cancer; 2005 Mar; 114(2):242-8. PubMed ID: 15543611
[TBL] [Abstract][Full Text] [Related]
18. Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer.
Wu X; Gu J; Dong Q; Huang M; Do KA; Hong WK; Spitz MR
Clin Cancer Res; 2006 Dec; 12(23):7194-201. PubMed ID: 17145846
[TBL] [Abstract][Full Text] [Related]
19. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
20. eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy.
Huang CI; Wang CC; Tai TS; Hwang TZ; Yang CC; Hsu CM; Su YC
PLoS One; 2019; 14(11):e0225537. PubMed ID: 31756179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
